- 1 Monocyte to Lymphocyte ratio is highly specific in diagnosing latent tuberculosis and declines
- 2 significantly following tuberculosis preventive therapy: a cross-sectional and nested prospective
- 3 *observational study*
- 4 Jonathan Mayito<sup>1</sup>, David B. Meya<sup>1</sup>, Akia Miriam<sup>1</sup>, Flavia Dhikusooka<sup>1</sup>, Joshua Rhein<sup>2</sup>, Christine Sekaggya-
- 5 Wiltshire<sup>1</sup>
- 6 1. Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda
- 7 2. Division of Infectious Diseases and International Medicine, Department of Medicine, University of
- 8 Minnesota, Minneapolis, Minnesota, United States of America

#### 9 Abstract

- 10 Interferon-gamma release assay and tuberculin skin test use is limited by costly sundries and cross-
- 11 reactivity with non-tuberculous mycobacteria and Bacille Calmette-Guérin (BCG) vaccination respectively.
- 12 We investigated the Monocyte to Lymphocyte ratio (MLR) as a biomarker to overcome these limitations
- and for use in monitoring response to tuberculosis preventive therapy (TPT). We conducted a cross-
- 14 sectional and nested prospective observational study among asymptomatic adults living with Human
- 15 Immuno-deficiency Virus (HIV) in Kampala, Uganda. Complete blood count (CBC) and QuantiFERON-TB®
- 16 Gold-plus were measured at baseline and CBC repeated at three months. Multivariate logistic regression
- was performed to identify factors associated with a high MLR and decline in MLR. We recruited 110 adults
- 18 living with HIV and on antiretroviral therapy, of which 82.5% (85/110) had suppressed viral loads, 71.8%
- 19 (79/110) were female, and 73.6% (81/110) had a BCG scar. The derived MLR diagnostic cut-off was 0.35,
- 20 based on which the MLR sensitivity, specificity, positive predictive value, and negative predictive value
- 21 were 12.8%, 91.6%, 45.5%, and 65.7% respectively. The average MLR declined from 0.212 (95% CI: 0.190
- 22 0.235) at baseline to 0.182 (95% CI: 0.166 0.198) after three months of TPT. A viral load of >50
- copies/ml (aOR, 5.67 [1.12-28.60]) was associated with a high MLR while that of <50 copies/ml (aOR, 0.07
- [0.007-0.832]) was associated with a decline in MLR. MLR was highly specific in diagnosing latent TB and
- declined significantly following three months of TPT. Implications of a high MLR and decline in MLR after
- 26 TPT need further evaluation in a larger cohort.
- 27 Key words: Monocyte to Lymphocyte ratio, MLR, latent tuberculosis diagnosis, tuberculosis preventive
- 28 therapy.

29

#### Background

- 30 Identification and preventive treatment of individuals with Mycobacterium tuberculosis (M. tuberculosis)
- 31 infection are critical in achieving the World Health Organization's (WHO) ambition to end the tuberculosis
- 32 pandemic by 2035 [1]. The Interferon Gamma Release Assay (IGRA) has a high specificity and negative
- 33 predictive value (NPV) for diagnosis of latent tuberculosis (TB), however, it's use is limited by the
- 34 requirement for sophisticated laboratory equipment, skilled human resources, and the inherent high cost
- of supplies required to carry out the test [2]. While on the other hand, the Tuberculin Skin Test's (TST)
- 36 cross-reactivity with the Bacillus Calmette-Guérin (BCG) vaccination and non-tuberculous mycobacteria,
- 37 leads to a low specificity of TST, which has been reported as low as 57% [3]. The above factors have limited
- 38 the deployment of IGRA and TST in resource-limited settings, which has led to the majority of clinicians
- 39 providing TB preventive therapy (TPT) to all individuals living with HIV with no evidence of active TB,

excluded by a negative WHO TB symptom screen. Moreover, it has been demonstrated that TPT is more beneficial for people who have a positive latent TB test [4], hence targeting TPT to individuals who are more likely to benefit from it would prevent unwanted exposure to TPT and be more economical.

 The WHO four symptom screen with absence of cough, weight loss, night sweats, and fever excludes active TB in individuals targeted for TPT [5]. Although a meta-analysis by Hamada *et al* showed that the symptom screen had a fairly good sensitivity when used to exclude active TB in antiretroviral therapy (ART) naïve people living with HIV (89.4%), the specificity was very low (28.1%) [6]. The sensitivity was however lower (51%) in patients on ART and in other conditions like pregnancy [6]. The sensitivity in patients on ART improved to 84.6% with the addition of the chest x-ray (CXR) but at the expense of specificity, which dropped from 55.5% to 29.8% [6]. The low specificity is of particular concern because of the dire consequences of exposure to inappropriate treatment, including driving the emergence of drug resistance [6]. The limitations of the IGRA, TST and the symptom-based screen necessitate alternative tools to improve the screening for latent TB and determining response to TPT.

There is currently no bacteriological, molecular, or radiological tool used to monitor response to TPT. Clinical monitoring for TB reactivation is the only available tool because IGRA and TST may not revert to negative following TPT [7, 8], due to the persistence of effector memory cells in absence of any continuing antigen stimulation. Based on the above dilemmas, there have been some attempts to develop alternative biomarkers for the diagnosis of latent TB and monitoring response to preventive therapy. *Mycobacterium tuberculosis* DNA in peripheral blood mononuclear cells has been evaluated as a biomarker for TB infection and monitoring response to TPT. A recent study described that the proportion of participants in whom *M. tuberculosis* DNA was detectable at baseline declined by 42% following TPT [9]. Despite their promise, *M. tuberculosis* DNA-based biomarkers still need further evaluation, and like IGRA, may not easily be deployed in limited resource settings.

Monocytes replenish macrophages [10], which are the primary effector cells against *M. tuberculosis* infection [11]. In addition, through the interferon-gamma (IFN-γ) signaling, *M. tuberculosis* biases hematopoiesis towards the proliferation of the myeloid hematopoietic stem cells (HSCs) rather than lymphoid cells, which include monocytes to propagate infection [12-14]. IFN-γ signaling activates the expression of interferon regulatory factors (IRF), which promote differentiation towards the myeloid lineage [12]. This leads to a higher Monocyte to Lymphocyte Ratio (MLR) in active TB compared to latent TB or healthy donors [15, 16]. The MLR, is a rapid and affordable biomarker that has the ability to discern latent TB from active TB, given that a higher MLR is seen in adults and children with active TB compared to latent TB ([16, 17]. An MLR cut-off of 0.38 in Kenyan children living with HIV had a sensitivity of 77%, specificity of 78%, positive predictive value (PPV) of 24%, and NPV of 97%, for the diagnosis of active TB [16]. A lower cut-off (0.29) in Italian HIV-uninfected adults had high sensitivity, 91%, and specificity, 94% [16]. Besides being useful in diagnosis, the MLR was also useful in monitoring treatment of active TB in children living with HIV with confirmed TB, in whom it declined significantly from 0.41 before treatment to 0.11 after treatment [18].

We, therefore, sought to compare the performance of the MLR versus IGRA in the diagnosis of latent TB, and to measure the change in MLR after three months of TPT among Ugandan adults living with HIV, in whom TB had been excluded using a negative WHO symptom screen [5]. The results from the study could bridge the gaps in diagnosing latent TB and monitoring the response to TB preventive therapy, where resources are limited.

### Methodology

This was a prospective observational study carried out between May and November 2021 at the Infectious Diseases Institute (IDI), Makerere University in Kampala, Uganda. The current standard of care is the provision of TPT to all people living with HIV and a negative TB symptom screen. We consecutively enrolled people living with HIV of 18 years and above, with no prior TB treatment, and a negative TB symptom screen, which included exclusion of patients with a cough, weight loss, fevers, and night sweats. A thorough physical examination for respiratory system abnormalities, lymphadenopathy, enlarged liver, spleen, and other relevant clinical features to exclude those with features suggestive of TB, was also performed. Participants with a negative symptom screen and no clinical findings suggestive of TB, were consented and administered the study questionnaire. The sample size was derived using the formula for diagnostic studies and a sample size of 105 participants gave an 80% chance of delineating the diagnostic performance of the MLR versus IGRA in diagnosing latent tuberculosis. The final sample size was 115, considering a 10% loss to follow up.

Individuals living with HIV were invited to give written consent to participate in the study after being briefed about the study. Consenting participants gave social demographic information, which was collected using the study questionnaire. Only authors who were part of the recruiting study team had access to the patient personal identifying data, which was kept as logs separate from the case record forms, under double local storage system. Information was collected on history of contact with an index pulmonary TB patient, smoking status, alcohol intake, BCG immunization status, and last HIV viral load results. Formal employment, private business, casual laborer, peasant, farmer, and others were the subcategories assessed for occupation. Given the need to have higher-powered subcategory numbers, the above were re-categorized according to the risk for M. tuberculosis infection, including congestion and other risky working and living conditions like ventilation and exposure to silica. Due to comparable risks posed, formal employment and private business were categorized as non-casual employment, while the rest were classified as casual employment or unemployment. Education was categorized as no education, primary and post primary education. To minimize bias, recruitment was spread over three months, calibrated instruments used to measure weight and height, and only the question on history of contact with an index pulmonary TB patient required remote recall. The outcome variables included a high or low MLR and a positive or negative IGRA.

Isoniazid 300 mg plus 25 mg pyridoxine daily for six months was initiated after intensive adherence counselling. Participants received three monthly drug refills and adherence support was provided through daily reminders by the next of kin and monthly phone call reminders by the study team.

Participants donated 5 ml of blood, of which 4 ml was used for IGRA and 1 ml for baseline complete blood count (CBC) testing. Another 1 ml of blood was collected after three months of TPT for the follow-up CBC. Absolute monocyte and lymphocyte counts were derived from these to calculate the MLR. The CBC was analyzed immediately using the Beckman Coulter Ac $\bullet$ T 5diff AL (Autoloader) Hematology Analyzer. Blood for IGRA testing was collected at baseline in specialized QuantiFERON tubes and transported to the laboratory at room temperature within 16 hours. The IGRA samples were incubated at 37°C for 16 to 24 hours, centrifuged at 3000g for 10 minutes, and the serum stored at -80°C until analysis, which followed the standard operating procedure provided by the Qiagen Company, the makers of the QuantiFERON kits. A positive IGRA was taken as a TB1 or TB2 antigen value minus the Nil sample value  $\ge$  0.35 and  $\ge$  25% of

- Nil and vice versa for the negative IGRA if the Mitogen value was  $\geq$  0.5, and if it was < 0.5 the result was
- taken to be intermediate. The IGRA and CBC tests were performed in the IDI Translation Research
- Laboratory and the IDI Makerere University-John Hopkins University (MUJHU) laboratory respectively.
- 127 Ethical approval was obtained from the Makerere University School of Biomedical Sciences Institutional
- 128 Review Board, reference number SBS 794. Written informed consent was obtained from all participants
- before any study-related procedures were conducted. The study did not include minors or vulnerable
- 130 groups.

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147148

149

150

151

159

### Statistical analysis

For descriptive analysis, continuous variables were reported as means with standard deviation (SD) for normally distributed data or median and interquartile range (IQR) for non-normally distributed data while categorical variables were reported as proportions in terms of frequencies and percentages. The MLR was derived from the ratio of the absolute monocyte count to the absolute lymphocyte count while the diagnostic cut-off for MLR was determined using the discriminant function analysis performed in excel. A function was generated from a sample of known positive and known negative cases based on the IGRA test. The function was then applied to the results of test diagnostic test (MLR) to classify them as positive or negative. Results of the discriminant analysis displayed a discriminant score and predicted group membership for each case. A value lower than the cut-off score represented a low MLR while the one above represented a high MLR. IGRA was used as the gold standard for diagnosis of latent TB. The sensitivity, specificity, PPV and NPV were determined from a 2X2 table of MLR and IGRA. A receiver operator curve (ROC) curve was plotted using sensitivity (y-axis) and 1-sensitivity (x-axis). A paired sample t-test was used to determine whether there was a statistically significant difference between mean MLR at baseline and that at follow up, while, a multivariate logistic regression analysis with forward stepwise logit function was employed to identify independent correlates of a high MLR and decline in MLR. Age, gender, BCG scar, viral load, body mass index (BMI), and IGRA status were included in the regression analysis based on the biological plausibility. A P<0.05 was considered statistically significant. Missing data including that, which was due to loss to follow up, was not included in the analysis.

## Results

## Study participant characteristics

- 152 Participant socio-demographic characteristics are shown in Table 1. Of the 110 people living with HIV
- recruited, 71.8% (79/110) were female and had a median age of 43 years (interquartile range (IQR), 30 -
- 154 51). The majority of the participants (49/110, 44.6%) were over the age of 45 years. Of these participants,
- 155 73.6% (81/110) had a BCG scar suggesting previous TB vaccination and 82.5% (85/110) had a suppressed
- viral load. All participants were receiving ART and they all received isoniazid for six months but the follow-
- up CBC measurement was at three months. Twenty-one percent (23/110) of participants did not complete
- 158 follow-up and therefore did not have follow-up CBC data.

## Diagnostic performance

- 160 We derived an MLR cut-off of 0.35 for the diagnosis of latent TB, indicating the presence of latent TB
- infection in individuals who scored above this value, i.e. high MLR. Based on this cut-off, the sensitivity,
- specificity, PPV, and NPV were 12.8% (95% CI: 6.6% 19.1%), 91.6% (95% CI: 86.4% 96.8%), 45.5% (95%

- 163 CI: 36.2% 54.8%), and 65.7% (95% CI: 56.8% 74.5%) respectively. The area under the curve was 0.45,
- 164 *figure* 1.

173

178

#### Effect of 3-month IPT on MLR

- A total of 87/110 participants with both baseline and three month follow-up MLR results were included
- in the analysis of the effect of isoniazid-based TPT on MLR. The average MLR for all participants
- significantly decreased from 0.212 (95% CI: 0.190 0.235) at baseline to 0.182 (95% CI: 0.166 0.198) at
- 3 months of TPT, representing a decline of 0.030 (95% CI: 0.007 0.053), table 2. We found that 52/87
- 170 (59.8%) of the participants had a decrease in MLR following three months of TPT, majority of which were
- 171 >45 years (27/52, 51.9%), were female (35/52, 67.3%), had a BCG scar (39/52, 75.0%), were IGRA negative
- 172 (34/53, 65.4%), and had a viral load of < 50 copies/ml (41/48, 85.4%), table 4.

## Factors associated with a high MLR at baseline and declining MLR

- 174 At bivariate analysis, only female gender (unadjusted odds ratio (OR), 0.28 [0.08-1.00]) was associated a
- high MLR, while, only an HIV viral load of >50 copies/ml (adjusted OR (aOR, 5.67 [1.12-28.60]) was
- associated with a high MLR at multivariate analysis, table 3. Only an HIV viral load of <50 copies/ml (aOR,
- 0.07 [0.007-0.832]) was associated with a decline in MLR, at multivariate analysis, table 4.

#### Discussion

- We have demonstrated a high specificity (91.6%) of MLR for diagnosis of latent TB using a cut off of 0.35,
- which is comparable to IGRA's (90%) [19] in people living with HIV. Based on this cut off, MLR had a lower
- sensitivity than IGRA (12.8% vs 64%) [20] in people living with HIV. To our knowledge, this is the first study
- demonstrating a low sensitivity but high specificity of MLR in diagnosing latent TB. Although MLR's limited
- sensitivity would prevent it from being used as a major diagnostic test for latent TB, its high specificity
- positions it as an inexpensive and simple biomarker that could be used to improve TB screening with the
- 185 WHO symptom screen.
- 186 The ability of MLR to monitor response to TB treatment has been observed in active TB, where there was
- a significant decline in MLR after six months of TB therapy and a persisting high MLR was associated with
- treatment failure [21]. We have demonstrated for the first time that MLR declined during TPT in the
- majority of participants. This could lead to a paradigm shift in the monitoring of response to TPT.
- 190 Currently, there is no laboratory or radiological test to monitor response to TPT. Given that TST and IGRA
- have low reversion rates following TPT [22, 23], clinical absence of active TB during and after TPT is
- currently the measure of effectiveness of TPT. Our results suggest that MLR is a potential TPT monitoring
- biomarker that can overcome the limitations of the current tests.
- 194 Among the factors studied, only HIV viral load was associated with a high MLR and a decline in MLR after
- 195 TPT. Participants with viral loads >50 copies/ml had a higher risk of having a high baseline MLR than those
- with a viral load of <50 copies/ml, while, participants with a viral load of <50 copies/ml were more likely
- to have a decline in MLR than those with a viral load >50 copies/ml. Due to the impaired immunological
- 198 response towards opportunistic infections, ongoing HIV replication, as indicated by a high viral load, is an
- independent risk factor for M. tuberculosis infection [24]. On the other hand, a suppressed viral load is
- 200 linked to immunological restoration and improved bacilli burden control, which aids response to TPT [25].

201 Our study had some limitations. First, the sample size was powered to study the diagnostic utility of the 202 MLR and not the factors associated with a high MLR. This could have limited our ability to clearly describe 203 factors associated with a high baseline MLR. Secondly, only 87 of the 110 participants had a complete pair 204 of baseline and follow-up MLR, which may have affected the evaluation of the factors associated with a decline in MLR. Thirdly, the effect of IPT was assessed after 3-months of isoniazid-based TPT rather than 205 206 six months, which may have underestimated the effect of TPT on the MLR. It also still needs to be clarified 207 what impact the one-month TPT regimen would have on the MLR response. 208 209 Conclusion 210 The MLR had high a specificity in the diagnosis of latent TB and declined significantly in the majority of 211 patients following TPT. These data if validated in larger cohorts, could improve the screening of latent TB 212 using the WHO four symptom screen and avail a biomarker that could monitor the response to TPT. 213 Recommendation 214 Larger studies are needed to further evaluate the effect of TPT on MLR and the implication of a high MLR 215 before and after TPT. 216 **Author contribution** 217 Jonathan Mayito, Conceptualization, Investigation, Methodology, Project Administration, Writing -218 **Original Draft Preparation** 219 David B. Meya, Conceptualization, Investigation, Methodology, Resources, Supervision, Writing – Review 220 & Editing 221 Miriam Akia, conduct of the study procedures, Writing – Review & Editing 222 Flavia Dhikusooka, statistical analysis, Review and Editing 223 Joshua Rhein, Conceptualization, Investigation, Methodology, Supervision, Writing – Review & Editing 224 Christine Sekaggya-Wiltshire, Conceptualization, Investigation, Methodology, Supervision, Writing -225 **Review & Editing** 226 **Conflict of interest** 227 All authors report no conflict of interest 228 Financial disclosure 229 Research reported in this publication was supported by the Fogarty International Center of the National 230 Institutes of Health under grant #D43TW009345 awarded to the Northern Pacific Global Health Fellows 231 Program. In addition, this research was funded in part, by the Welcome Trust 107742/Z/15/Z and the UK 232 Foreign, Commonwealth & Development Office, with support from the Developing Excellence in 233 Leadership, Training and Science in Africa (DELTAS Africa) program. For the purpose of open access, the

author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising

234

235

from this submission.

- The funders had no role in study design, data collection and analysis, decision to publish, or preparation
- 237 of the manuscript.

239

#### References

- 240 1. WHO, The END TB Strategy. [Internet], 2015.
- 241 2. Geneva: World Health Organization, *Use of Tuberculosis Interferon-Gamma Release Assays* (IGRAs) in Low- and Middle- Income Countries: Policy Statement. [Internet], 2011.
- Adams S, et al., Evaluating Latent Tuberculosis Infection Test Performance Using Latent Class
  Analysis in a TB and HIV Endemic Setting. Int J Environ Res Public Health, 2019 Aug. 16(16): p.
  2912.
- 246 4. Den Boon S, et al., *Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV.* AIDS, 2016 Mar. **30**(5): p. 797-801.
- 5. WHO, WHO TB KNOWLEDGE SHARING PLATFORM: WHO-recommended four-symptom screen. [Internet], 2021.
- Hamada Y, et al., Sensitivity and specificity of WHO's recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis. Lancet HIV, 2018 Sep. **5**(9): p. e515-e523.
- 253 7. Esmail H, Barry CE, and W. RJ, *Understanding latent tuberculosis: the key to improved diagnostic* 254 and novel treatment strategies. Drug Discov Today, 2012 May. **17**(9-10): p. 514-21.
- Tapaninen P, et al., Effector memory T-cells dominate immune responses in tuberculosis treatment: antigen or bacteria persistence? Int J Tuberc Lung Dis, 2010 Mar. **14**(3): p. 347-55.
- 9. Belay M, et al., *Detection of Mycobacterium tuberculosis complex DNA in CD34-positive* peripheral blood mononuclear cells of asymptomatic tuberculosis contacts: an observational study. The Lancet Microbe, 2021 Jun. **2**(6): p. E267-E275.
- Hume DA, Irvine KM, and Pridans C, *The Mononuclear Phagocyte System: The Relationship between Monocytes and Macrophages* Trends in Immunology, 2019 Feb. **40**(2).
- 262 11. Kaufmann SHE, *Protection against tuberculosis: cytokines, T cells, and macrophages.* Annals of the Rheumatic Diseases, 2002. **61**: p. ii54-ii58.
- de Bruin AM, et al., IFNγ induces monopoiesis and inhibits neutrophil development during
  inflammation. Blood, 2012. 119: p. 1543-1554.
- Morales-Mantilla DE and K. KY, The Role of Interferon-Gamma in Hematopoietic Stem Cell
  Development, Homeostasis, and Disease. Curr Stem Cell Rep, 2018. 4(3): p. 264-271.
- 268 14. Baldridge MT, et al., *Quiescent haematopoietic stem cells are activated by IFN-γ in response to chronic infection.* Nature 2010 June. **465**: p. 793-797.
- Naranbhai V, et al., Ratio of monocytes to lymphocytes in peripheral blood identifies adults at
  risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy. J Infect
  Dis, 2014 Feb. 209(4): p. 500-9.
- La Manna MP, et al., Quantitative and qualitative profiles of circulating monocytes may help
  identifying tuberculosis infection and disease stages. PLOS ONE 2017 Feb 12(2): p. e0171358.
- Naranbhai V, et al., Distinct transcriptional and anti-mycobacterial profiles of peripheral blood
  monocytes dependent on the ratio of monocytes: lymphocytes. EBioMedicine, 2015. 2(11): p.
  1619±26.
- 18. Choudhary RK, et al., Monocyte-to-Lymphocyte Ratio Is Associated With Tuberculosis Disease
  279 and Declines With Anti-TB Treatment in HIV-Infected Children. J Acquir Immune Defic Syndr,
  280 2019 Feb. 80(2): p. 174-181.

- 281 19. Kussen GMB, et al., Interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among HIV patients in Brazil. Braz J Infect Dis, 2016 Jan-Feb. **20**(1).
- 283 20. Chen H, et al., Diagnostic accuracy of the interferon-gamma release assay in acquired
  284 immunodeficiency syndrome patients with suspected tuberculosis infection: a meta-analysis.
  285 Infection, 2022. 50: p. 597–606.
- 21. Adane T, et al., Accuracy of monocyte to lymphocyte ratio for tuberculosis diagnosis and its role in monitoring anti-tuberculosis treatment: Systematic review and meta-analysis. Medicine, 2022. **101**: p. 44(e31539).
- 289 22. Zwerling A, et al., *Interferon-gamma release assays for tuberculosis screening of healthcare* 290 *workers: a systematic review.* Thorax, 2012. **67**: p. 62-70.
- Johnson DF, et al., Tuberculin Skin Test Reversion following Isoniazid Preventive Therapy Reflects
  Diversity of Immune Response to Primary Mycobacterium tuberculosis Infection. PLoS ONE,
  2014. 9(5): p. e96613.
- 294 24. Fenner L, et al., *HIV viral load as an independent risk factor for tuberculosis in South Africa:* collaborative analysis of cohort studies. J Int AIDS Soc, 2017. **20**(1): p. 21327.
- 25. Karo B, et al., *Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy.* BMC Infect Dis, 2017. **17**: p. 517.




Figure 1: Study flow chart

313

314

## **Table1: Socio-demographic characteristics**

Variable	Frequency	Percentage (%)	
Age (years)			

Below 25	16	14.55
25-45	45	40.91
>45	49	44.55
Education		
No education	4	3.67
Post Primary	70	64.22
Primary	35	32.11
Employment		
Non casual	57	51.82
Casual	53	48.18
Alcohol		
No	87	79.09
Yes	23	20.91
Smoking history		
Never smoked	106	96.36
Current smoker	4	3.64
BCG Status		
No	29	26.36
Yes	81	73.64
IGRA test		
Negative	71	64.55
Positive	39	35.45
HIV Viral load (copies/ml)		
<50	85	82.52
>50	18	17.48




Figure 1: The Receiver Operative Curve for the diagnostic utility of MLR

## 319 Table 2: Effect of IPT on MLR

316

317

318

320

321

Variable	Obs	Mean	Std. Err.	Std. Dev.	[95% Conf.	Interval]
Baseline MLR	87	0.2121839	0.011318	0.105571	0.1896837	0.234684
Follow-up MLR	87	0.182069	0.007846	0.073186	0.166471	0.197667
Difference	87	0.0301149	0.011742	0.109518	0.0067735	0.053456

# Table 3: Factors associated with a high MLR

	Category	Proportion with high MLR	Bivariate analysis		Multivariate analys	is
Variable	_					
			Unadjusted odds ratios	P-values	Adjusted odds ratios	p- values
Age	<25	1(11.11%)	Ref		Ref	
	25-45	1(11.11%)	0.15[0.01-3.09]	0.21	0.13[0.01-2.05]	0.148
	>45	7(77.78%)	1.05[0.09-11.82]	0.968	1.27[0.17-9.1]	0.809
Gender	Male	6(54.55%)	Ref	Ref		

	Female	5(45.45%)	0.28[0.08-1.00]	0.040	0.33[0.08-1.5]	0.148
1 Education	None	0	1		1	
	Post- primary	7(87.50%)	Ref		Ref	
	Primary	1(12.50%)	0.25[0.028-2.211]	0.211	0.09[0.003-2.80]	0.168
BCG scar	Yes	7(77.78%)	Ref		Ref	
	No	2(22.22%)	0.83[0.15-4.62]	0.833	2.23[0.40-12.32]	0.358
Viral load	<50	5(62.50%)	Ref		Ref	
	>50	3(37.50%)	3.76[0.94-15.06]	0.061	5.67[1.12-28.60]	0.036
IGRA status	Negative	5(55.56%)	Ref		Ref	
	Positive	4(44.44%)	1.66[0.38-7.15]	0.68	1.76[0.38-8.09]	0.470
BMI	N/A	N/A	1[0.91-1.09]	0.943	1[0.91-1.07]	0.703
Employment	Non- casual	4(44.44%)	Ref			
	Casual	5(55.56%)	1.43[0.34-6.10]	0.623	N/A	N/A
2 Alcohol	No	6(66.67%)	Ref			
intake	Yes	3(33.33%)	1.65[0.35-7.82]	0.528	N/A	N/A

Employment (1) and alcohol intake (2) were not significant at bivariate analysis and did not fit in the final multivariate model. N/A = Not applicable

Table 4: Factors associated with a decline in MLR

	Category	Proportion with decline in MLR	Bivariate analysis		Multivariate analysis	
Variable	_					
			Unadjusted odds ratios	P- values	Adjusted odds ratios	p- values
Age	<25	21 (40.38%)	Ref		Ref	
	25-45	4 (7.69%)	0.15[0.01-3.09]	0.21	0.2[0.015-2.65]	0.222
	>45	27 (51.92%)	1.05[0.09-11.82]	0.968	1	
Gender	Male	17 (32.69%)	Ref		Ref	
	Female	35 (67.31%)	0.31[0.071-1.352]	0.119	0.28[0.04-2.04]	0.210
BCG scar	Yes	39 (75.00%)	Ref		Ref	
	No	13 (25.00%)	0.83[0.15-4.62]	0.833	1.28[0.13-12.93]	0.836
Viral load	<50	41 (85.42%)	0.19[0.03-1.08]	0.061	0.07[0.007-0.832]	0.035
	>50	7 (14.58%)	Ref			
IGRA status	Negative	34 (65.38%)	Ref		Ref	
	Positive	18 (34.62%)	1.66[0.38-7.15]	0.68	0.79[0.09-6.59]	0.828
ВМІ	N/A	N/A	1[0.91-1.09]	0.943	1.04[0.93-1.16]	0.524
1 Education	None	2 (3.92%)	1		N/A	N/A
	Post- primary	33 (64.71%)	Ref		N/A	N/A
	Primary	16 (31.37%)	0.25[0.028-2.211]	0.211	N/A	N/A

2 Employment	Non- casual	25 (48.08%)	Ref		Ref	
	Casual	27 (51.92%)	1.43[0.34-6.10]	0.623	N/A	N/A
3 Alcohol	No	39 (75%)	Ref		N/A	N/A
intake	Yes	13 (25%)	1.65[0.35-7.82]	0.528	N/A	N/A

Education (1), employment (2), and alcohol intake (3) were not significant at bivariate analysis and did not fit in the final multivariate model. N/A = Not applicable

326

327